The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

3rd Gene Therapy Potency Assay Summit 2025 With PTC Therapeutic’s Kebilidi hitting the market last year, 2025 marks a pivotal moment for drug developers and analytical teams.

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

Conclusion: This study introduces a systematic framework that integrates LLMs with human expertise for gene prioritization. Our analysis identified CD38, TNFRSF17, and IGJ as the top candidates within ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

Blenrep (belantamab mafodotin) becomes the first BCMA-targeted drug for myeloma to be approved in the EU, and according to its label can be used to treat the blood cancer in adult patients who ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

AstraZeneca’s collaboration with Cellectis leverages that company’s gene-editing technology. This partnership spans allogeneic cell therapies currently in preclinical development for cancer.